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Abstract
The subject of this paper is the regulation of dietary supplements, with the passage of the Dietary Supplement
Health and Education Act of 1994 (DSHEA) marked as a turning point. The paper examines the history
of regulation prior to DSHEA, and then it proceeds to examine DSHEA itself as legislation. The problems
with DSHEA and its enforcement by the Food and Drug Administration (FDA) are then discussed, and I
use ephedra as a speciﬁc example in illustrating those problems. To complete the examination of the entire
regulatory scheme behind dietary supplements, I then address the concurrent regulatory responsibilities that
the Federal Trade Commission (FTC) has with the FDA in regulating supplements. As a counterpoint to
government regulation, I also examine some areas of products liability law that will be relevant in dietary
1supplement litigation as an illustration of private regulation via litigation. I conclude the paper by discussing
some proposals that can be implemented to improve the dietary supplement regulatory scheme.
2I. Introduction
The presence of dietary supplements in the American mainstream culture and economic markets
has boomed in the last several years. According to a recent issue of U.S. News and World Report,
approximately 123.5 million Americans have used dietary supplements to treat a variety of health
conditions.1 In 1999, United States consumers spent approximately $31 billion for dietary
supplements and certain food products that claim to have additional health benefits beyond
basic nutrition.2 When one enters a supermarket or a drugstore, it is a common sight to see
a growing number of dietary supplements that promise to do things such as combat stress, reduce
cholesterol levels, eliminate cellulite, improve mental alertness, and sharpen memory.
Manufacturers of these supplements often intentionally select brand names or use words on their
labels and in promotional materials to imply the improbable or impossible: ‘‘fat burner’’
or ‘‘detoxifies.’’ For example, consumers can buy ‘‘natural Viagra,’’ the ‘‘#1 rated herbal’’
for impotence.3 Manufacturers of these supplement products have jumped on the opportunity
to take liberties with regard to health claims on labels. They can state the manner in which
the product is intended to ‘‘affect the structure or function of the body’’4 but cannot claim
its use for a specific disease. We often see examples where the manufacturer can just claim
that their product promotes ‘‘wellness’’ as opposed to ‘‘sickness,’’ or that their product
‘‘promotes regularity’’ as opposed to ‘‘treating constipation,’’ and under existing laws, these
1Amanda Spake, Natural Hazards, U.S. News And World Report, Feb. 12, 2001
2United States General Accounting Office, Report to Congressional Committees, Food Safety: Improvements
Needed in Overseeing the Safety of Dietary Supplements and ‘‘Functional Foods’’, GAO/RCED-00-156 (July 2000)
3Paul D. Rheingold, Association of Trial Lawyers of America Winter Convention Reference Materials -- Hot
Topics: Bitter Pill: Indications / Complications in Drug Litigation, Ephedra and Other Dangerous Herbals --
and Its Cousin PPA (Winter 2001)
421 U.S.C. §321 (g)(1)(C) (1994 & Supp. III 1997)
3claims would be allowable.
This paper will primarily focus on examining the evolution of the regulatory scheme that governs
the dietary supplement industry today. In Section II, I summarize how dietary supplements
were regulated prior to 1994. In Section III, I discuss the changes that occurred in 1994
as a result of the passage of the Dietary Supplement Health and Education Act (DSHEA). In Section
IV, I address the problems that are associated with DSHEA and its enforcement by the Food and
Drug Administration. In Section V, I examine a specific example of a dietary supplement ingredient,
ephedra, to show how manufacturers have abused the loopholes in DSHEA and the regulatory scheme.
In Section VI, I flesh out the remainder of the examination of the regulatory scheme by discussing
FTC regulation of dietary supplements and its problems. I also discuss the areas of law that
may be involved in dietary supplement litigation, as they a form of private regulation of the
industry, as opposed to governmental regulation. In Section VII, I conclude by addressing
some possible changes that can improve the current regulatory scheme.
II. Background of the Dietary Supplement Health and Education Act (DSHEA)
Much of this explosive dietary supplement phenomenon can be traced to 1994, when Congress enacted
the DSHEA in an effort to protect consumers’ right to purchase dietary supplements. DSHEA
is arguably one of the most important examples of a deregulation of a federal health and safety
program.
Before examining DSHEA, it is important to discuss the regulatory procedures and institutions
that preceded it. Prior to DSHEA, the Food and Drug Administration (FDA) regulated dietary
4supplements as ‘‘food, drugs, or both.’’5 The FDA typically used its authority over drugs
and food additives, as stated in the FDCA provisions, to regulate these dietary supplements.
A dietary supplement manufacturer seeking to sell its product as a drug was required to obtain
pre-market approval from the FDA showing that the proposed product was safe, and also effective
if the manufacturer wanted to make a drug claim.6 Drugs may only enter the product market
if they survive the FDA’s ‘‘new drug approval’’ (NDA) review process.7 This rigorous pre-market
approval process often involves a significant duration of time in order to ensure that the
claims are supported by ‘‘adequate and well-controlled investigations.’’8 There are generally
two types of the above-mentioned drug claims. The first type relates to therapeutic claims
to treat or prevent disease. The second type, which is more relevant to this paper, includes
claims that purport to ‘‘affect the structure or function of the body.’’9 This second type
of claim was originally included in legislation because Congress had been convinced by the
proposition that the claims language needed to be expanded in order to facilitate the regulation
of various products that do not necessarily treat disease, as traditionally understood.
The FDA’s power to regulate dietary supplements as drugs was upheld in a landmark case in 1948,
Kordel v. United States.10 In that case, the Supreme Court broadly defined the term labeling
to include statements made within leaflets and pamphlets mailed separately by the dietary supplement
manufacturer to the retailer. Thus, the Court concluded that the FDA could invoke its authority
over drugs against dietary supplements such as herbal remedies when the information pamphlets
accompanying the product suggest a use of disease prevention or treatment or a use that affects
5FDA Advance Notice of Proposed Rulemaking, Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, at
33692 (1993)
621 U.S.C. §355 (d) (1994)
721 U.S.C. §321 (p)(1) (1994)
821 U.S.C. §355 (d) (1994)
9See supra note 4
10335 U.S. 345 (1948)
5body structure or function. The ultimate effect of the FDA’s use of its authority over drugs
was to prevent the marketing of these products until the pre-market approval for both safety
and effectiveness was obtained.
Also, the FDA often used its authority to regulate food additives as an easier means of declaring
a dietary supplement ingredient unsafe or inadequately tested. If the FDA declared that the
dietary supplement was not safe according to the food additive provisions of the Federal Food,
Drug, and Cosmetic Act (FDCA)11, then the manufacturer would have the burden of proving that
the supplement in question was exempt from such requirements.
The more typical scenario of regulation involved dietary supplements that were sold as foods,
not drugs. As noted, the process for approving drug claims is a rigorous one. Foods, however,
when they claim to affect the body’s structure or function, are not considered drugs; food
products can make ‘‘structure-function’’ claims without FDA approval.12 The statute indicates
that foods inherently have these effects on body structure and function. On the other hand,
according to the courts, supplements were only able to fit into the food classification if
their claims related to food uses, such as aroma, nutrition, or taste.13 So, claims about
these food uses, including nutritional effects would be acceptable, and we often saw these
kinds of claims with supplements such as vitamin pills. But, other claims about the effects
of the supplements, including reducing cholesterol, increasing memory, and other claims we
often see currently, were still considered drug claims, and thus subject to more stringent
review by the FDA. Manufacturers typically did not want to run the risk of having their products
classified as drugs on the basis of a structure-function claim, so the practical effect was
11Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended 21 U.S.C. §§ 301 et. Seq. (1994))
1221 U.S.C. §321 (g)(1) (1994)
13Nutrilab, Inc, v. Schweiker, 713 F.2d 335, 338 (7th Cir. 1983)
6one that limited the claims made on their dietary supplement products. For instance, manufacturers
of St. John’s Wort could not refer to its alleged mood-brightening qualities despite its history
of antidepressant efficacy.
Still, even before the passage of the DSHEA in 1994, the courts and Congress reacted to what
was perceived to be FDA over-regulation of these products, and this legislative and judicial
action has had the effect of limiting FDA’s authority to regulate supplements as drugs based
merely on consumer use without additional evidence to show the manufacturer’s intent to market
their product as a drug.14
For example, during the 1960’s, the FDA took a more aggressive position in regulating vitamin
and mineral supplements.15 It was concerned by the elevated use of higher dosages of vitamins
and minerals, and it used its drug authority as the primary regulatory tool. This increased
regulation escalated, and in 1973, the FDA drafted regulations that prohibited irrational combinations
of vitamins and minerals when sold as foods, and set the maximum and minimum potency levels
for nutrients.16 If a nutrient’s potency level exceeded the maximum threshold set by the FDA,
then the agency would regulate that product as an unapproved drug.
These new regulations were challenged in federal court in National Nutritional Foods Ass’n v. FDA.17
The court held that the FDA was allowed to establish limits for vitamin and mineral doses in
order to protect consumers from being confused about the therapeutic effects.18 More importantly,
however, the court ruled that the mere fact that a nutrient is sold in high doses will not
automatically subject it to regulation as an unapproved drug, as the FDA had originally intended.19
14Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 671 (1997)
15See id. at 673
16Definitions and Standards of Identity for Food and Special Dietary Uses, 38 Fed. Reg. 20730, 20738
(1973)
17504 F.2d 761, 789-92 (2d Cir. 1974)
18See id.
19See id. at 789
7The court’s holding weakened the FDA’s drug authority as a regulatory tool against dietary
supplements because the FDA would now have to satisfy an escalated burden of proof in order
to establish that the manufacturer intended consumers to use its product as a drug therapy.
This momentum against regulation led to subsequent lobbying efforts that resulted in the passage
of the Proxmire Amendment.20 The Amendment codified the holding in National Nutritional Foods Ass’n
that prohibited the FDA from using drug authority against a vitamin or mineral product merely
because the level of potency exceeds the FDA recommended level. The Amendment also nullified
the FDA’s authority to subject vitamins and minerals to regulation for the sole reason of irrational
combinations or high dosage.
Another example of the weakening of FDA authority occurred in Fmali Herb, Inc. v. Heckler.21
At stake was the FDA argument that the grandfather exemption22 for commonly used food additives
in existence prior to 1958 exempted only those additives that were present in the country before
1958; the FDA sought to exclude various traditional herbs and substances that were used in
Chinese and other cultures using this exemption. However, the FDA suffered a defeat when the
Fmali Herb court ruled against it and allowed herbal ingredients used widely outside of the
country to fall within the grandfather exemption.23 The FDA food additive authority against
herbal supplements was weakened by this decision.
Now with the FDA’s drug and food additive authority weakened, the FDA assumed a more reactive
role in regulation, often acting in response to safety problems or explicit drug claims, as
opposed to enforcing a standard requiring manufacturers to prove their products’ lack of harm.24
Its regulatory stance against dietary supplements had to be relaxed. The Proxmire Amendment
2021 U.S.C. §350 (1994)
21715 F.2d 1385 (9th Cir. 1983)
2221 U.S.C. §321(s) (1994)
23See supra note 21, at 1389-90
24United States General Accounting Office, Report to Senator Kennedy, at 4 (B252966, July 2, 1993)
8and the court decisions discouraged the agency from engaging in routine and close regulation
of the dietary supplement product market. During this era of scaled-back enforcement and regulation,
the FDA’s reactive role, as under their food authority, consisted of enforcing the pre-market
approval requirements on manufactures when a specific safety issue arose regarding a food additive.
Under its drug authority, the FDA pursued enforcement when the labeling of the product had
unauthorized drug claims. Under this scaled-back regulation, it was much easier for supplement
manufacturers to bring their products into the consumer market, and this was evidenced by the
surge in the number of supplements on the market in the early 1990’s. Naturally, the increased
availability of these products gave consumers the new opportunity to abuse or misuse them,
in the sense that the uses were neither approved by the FDA nor indicated on the product labeling.
A turning point in this period of reduced FDA regulation occurred in 1993 when thirty-eight
deaths and fifteen hundred adverse effects were attributed to L-tryptophan, an amino acid that
approximately thirty million Americans used as an antidepressant or as an aid to body-building.25
The FDA employed a Task Force to weigh different options in connection with issues raised by
not only L-tryptophan, but also all dietary supplements.26 The Task Force recommended in its
report that L-tryptophan and other amino acids be regulated as drugs because their ‘‘primary
intended use... is for therapeutic rather than nutritional purposes,’’ and because they were
marketed heavily.27 In addition, the FDA was concerned that many supplements that were on
the market had ‘‘no known history of food use and, even without drug claims are used for medical
purposes.’’28 Further, the Task Force explored ‘‘Issues of Concern’’ about herbal supplements
and pointed out that the FDA’s immediate goal was ‘‘to ensure their safety and to remove hazardous
25See supra note 5, at 33,695-66, and 33,698-99
26Id. at 33,694-99
27Id. at 33,697
28Id.
9products from the market...in accordance with the priorities established in FDA’s health fraud
program.’’29 Despite these strong statements, the Task Force still appeared to only have desired
to target specific enforcement at very serious product frauds and safety risk, as it ‘‘attempted
to balance the agency’s statutory mandate to protect the public health with some accommodation
of the desire of a substantial segment of the public to obtain dietary supplements, including
ones with possibly little or no documented nutritive value.’’30
However, for many, this event signaled an FDA return to the stronger regulatory era that preceded
the Proxmire Amendment, when it tried to classify high-dosage vitamins as drugs based upon
widespread consumer use. In response to the Task Force’s finding, the dietary supplement industry
moved to appeal to the public. The industry characterized the FDA’s new approach as having
extensive reach and threatening to take many products, including basic vitamins and minerals,
away from the consumer market. This marked the beginning of momentum for the passage of DSHEA.
Another impetus toward the movement for DSHEA was the FDA’s interpretation of the Nutrition
Labeling and Education Act of 1990 (NLEA).31 The NLEA allowed conventional foods to assert
certain health claims that met an evidentiary standard of ‘‘significant scientific agreement,’’
and were approved by the FDA.32 The NLEA appeared to give the opportunity for health claims
to describe a relationship between dietary supplements and disease, and it gave the FDA decision
whether or not to employ a lower standard for scientific proof for approval of these health
claims on dietary supplements.33 The FDA decided to hold herbal supplement manufacturers to
29Id. at 33,698
30Id. at 33,691
31Pub. L. No. 101-535, 104 Stat. 2353 (1990) (codified as amended at 21 U.S.C. §§301, 321, 337, 343, 345,
371 (1994))
3221 U.S.C. §343(r) (1994)
33Nutrition Labeling and Education Act of 1990, §3 (b)(1)(A)(x)
10the higher standard of ‘‘significant scientific agreement,’’ and declined to approve health
claims for dietary supplements such as linking dietary fiber and cancer, antioxidant vitamins
and cancer, and omega-3 fatty acids and heart disease.
By 1993, dietary supplement manufacturers and consumers realized that the era of reduced enforcement
of FDA regulations against dietary supplements during the 1970’s and 1980’s might be coming
to an end. The FDA appeared more than willing to use its authority against suspect supplements,
but consumer demand for these supplements was still increasing. In response, interest groups,
the dietary supplement industry, and supplement consumers banded together. There was a national
‘‘blackout day’’ in which retailers of these dietary supplements covered all the dietary supplements,
which might be taken away by the FDA under its new expansive regulatory goals, with black fabric.
This arguably marked the symbolic beginning of a public grassroots consumer letter writing
campaign, largely organized by the supplement industry, for legislation that eventually became
the Dietary Supplement Health and Education Act.
III. The Dietary Supplement Health and Education Act of 1994 (DSHEA)
Because the popular support for DSHEA was so overwhelming, it became law on October 25, 1994,
and it took effect in 1996. For millions of consumers of dietary supplements, they viewed
this passage of law as an enormous victory under the threat of unreasonable regulatory guidelines
advocated by the FDA. Meanwhile, the passage of DSHEA was viewed as a failure and defeat from
the FDA’s perspective, and it has been described as Commissioner Kessler’s ‘‘greatest failure’’
11as the head of the FDA.34
The text of the statute directly addresses the concern of FDA over-regulation by asserting
that ‘‘the Federal Government should not take any actions to impose unreasonable regulatory
barriers limiting or slowing the flow of safe products and accurate information to consumers’’
and that ‘‘dietary supplements are safe within a broad range of intake, and safety problems
with the supplements are relatively rare.’’35 The statute further asserts that ‘‘improving
the health status of United States citizens ranks at the top of the national priorities of
the Federal Government’’ and that ‘‘the importance of nutrition and the benefits of dietary
supplements to health promotion and disease prevention have been documented increasingly in
scientific studies.’’36 Before proceeding further, I will summarize the three major changes
that have occurred since the passage of DSHEA.
The first major change under DSHEA involves the redefinition of dietary supplements. Dietary
supplements are now vaguely redefined as a new category distinct from food and drugs: a product
(other than tobacco) intended to supplement the diet that bears or contains one of more of
the following ingredients: (A) a vitamin; (B) a mineral; (C) a herb or other botanical; (D)
an amino acid; (E) a dietary substances for use by man to supplement the diet by increasing
the total dietary intake; or (F) a concentrate, metabolite, constituent, extract or combination
of any ingredient described in clause (A), (B), (C), (D), or (E).37 Any product that fits within
this broad definition is eligible for sale in stores, and its manufacturer is now legally able
to make health-like claims as long as it has some scientific evidence for them. This expansive
definition of dietary supplement has led to an explosion in the amount of dietary supplements
34Marion Burros, ‘‘F.D.A. Commissioner Is Resigning After 6 Stormy Years in Office,’’ New York Times, Nov.
26, 1996, at A1
35Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994), §2
36Id.
3721 U.S.C. §321
12we now see in retailers after the passage of DSHEA.
Going past the definitional revision, the second major change made by the DSHEA is in connection
with labeling. Now, provided the requirements outlined by the statute is satisfied, it is
allowable for dietary supplements to make statements about the role of a ‘‘dietary ingredient’’
in affecting ’’the structure or function of the body’’ without have the statement being considered
a drug claim by the FDA.38 In order to satisfy the statutes’ requirements, such a claim must
be accompanied by an information disclosure that ‘‘statement has not been evaluated by [the
FDA]’’ and the product ‘‘is not intended to diagnose, treat, cure, or prevent disease.’’39
Also, the dietary supplement manufacturer has to substantiate that their claim is ‘‘truthful
and not misleading.’’40 The biggest difference between these claims made by dietary supplements
and traditional drug claims is that there is no requirement for prior FDA approval of the statement.41
Section six of the DSHEA outlines the statements of nutritional support that are allowed in
dietary supplement labeling. These include a statement that: 1) claims a benefit related
to a classical nutrient deficiency disease and discloses the prevalence of such disease in
the United States, 2) describes the role of a nutrient of dietary ingredient intended to affect
the structure or function in humans, 3) characterizes the documented mechanism by which a nutrient
or dietary ingredient acts to maintain such structure or function, and 4) describes general
well-being from consumption of a nutrient or dietary ingredient.42 This is a very significant
provision in the statute because as noted above, previous to the DSHEA, the courts held that
the definition of ‘‘food’’ only included the standard foods ingested primarily for the purposes
3821 U.S.C. §343(r)(6)(A) (1994)
3921 U.S.C. §343(r)(6)(C) (1994)
4021 U.S.C. §343(r)(6)(B) (1994)
41Id.
42DSHEA, supra note 35, §6
13of ‘‘taste, aroma, or nutritive value.’’43
The statute further suggests that these claims can be made for nutrients and also for ‘‘dietary
ingredients.’’44 So, it appears that claims for dietary supplements would be allowable even
if the claim were not connected to nutrition directly. For example, we have seen such claims
to include claims about the role of a nutrient or dietary ingredient regarding the structure
or formation of the human body, and declarations of general well bring from the consumption
of a nutrient or other dietary ingredient. This differs from the past where a test that was
used for food supplement claims had been a determination of nutritional value. So, the major
effect of the DSHEA provision regarding claims is to permit herbs, botanical and other products
to be sold as dietary supplements and to make claims about their effects and benefits despite
the understanding that they are not foods in the traditional nutritional sense and despite
the fact that these products often have been used as medicines in other foreign countries.
The third major change brought by DSHEA was the shifting of the burden of proving product safety
from the manufacturer to the FDA. Currently, a dietary supplement will be considered ‘‘safe’’
if the new ingredient does not present a significant or unreasonable risk of illness or injury
under conditions of use recommended in the product labeling.45 Should the FDA attempt to remove
a dietary supplement from the product market, it must demonstrate that the supplement would
be harmful if consumed as recommended.
However, the FDA is not without any regulatory teeth. If the FDA concludes that a product
poses an ‘‘imminent hazard to public safety,’’ the agency may immediately remove that product
from the market, but it must initiate a proceeding afterwards to evaluate that decision.46
43See supra note 13.
4421 U.S.C. §343(r)(6)(A) (1994)
4521 U.S.C. §342(4) (1994)
4621 U.S.C. §342 (f)(1((C) (1994)
14Furthermore, the FDA is able to take action if a dietary supplement ‘‘is or contains a dietary
ingredient that renders it adulterated... under the conditions of use recommended or suggested
in the labeling of such dietary supplement.’’47 For example, the FDA, after receiving reports
of serious injuries and deaths, concluded that Nature’s Nutrition Formula One, a dietary supplement
supposedly produced from ma huang and kola nut, posed a significant risk of illness or injury.48
Thereafter, the FDA issued a warning letter to the product manufacturer advising that its product
was adulterated and unsafe, and the owner later pleaded guilty and served some jail time.49
Nonetheless, most of the time, this burden shifting to the FDA to prove product safety has
made it much more challenging for the agency to remove a dietary supplement from the consumer
market than it has in the past. The shift in the burden of proof to the FDA forces the agency
to make very hard resource allocation decisions. In the area of dietary supplement regulation,
this has unfortunately translated into supplement manufacturers being more easily able to market
its products liberally without any imminent threat of close regulatory monitoring.
IV. New Problems Related to DSHEA and its Enforcement by the
FDA
As has been suggested, DSHEA has elements of vagueness in its language. In the definition
of ‘‘dietary supplement,’’ the meaning of ‘‘dietary’’ is not stated, nor is the catch-all provision
in subsection (E) of 21 U.S.C. §321(ff)(1). But perhaps the largest and most important difficulty
4721 U.S.C. §342 (f)(1)(D) (1994)
48Vani Singhal, FDA’s Regulation of Dietary Supplements Fueled by Industry Growth, 1 Pharmaceutical & Med.
Devices L. Bull. 5 (2001)
49Id.
15with the new statute lies in the question of how to distinguish disease/drug claims from the
permissible claims that relate to structure and function. This is a very significant difficulty
because since the passage of DSHEA, many manufacturers are deciding to forgo efforts to gain
FDA approval for health claims and instead are marketing their products as dietary products
on the basis of structure-function claims, which as noted can be made without prior FDA approval.
The FDA itself has recognized the troubling nature of this part of DSHEA, and it has stated
that diseases, ‘‘by definition, adversely affect some structure and function of the body.’’50
It is true that distinguishing between structure-function claims and disease claims is not
as significant for drug regulation since both kinds of claims require pre-market approval from
the FDA. However, since DSHEA permits structure-function claims for dietary supplements, the
issue of how to draw the line between these two kinds of claims has become even more important.
The FDA has attempted to identify some elements to help clarify the line between disease claims
and structure-function claims in its rulemaking.51 I will try to briefly highlight below some
of the more important elements that the FDA has recognized under its rules.
While the supplement manufacturing industry has tried to maintain that a claim is only a disease
claim if it makes an express reference to a disease, the FDA has not adopted that position,
and it has continued to disallow implied disease claims for dietary supplements. Instead,
the FDA has taken the position that while disease claims refer to specific diseases, statements
that ‘‘refer broadly to body systems or functions without sufficient reference to specific
abnormalities or symptoms to be understood as references to particular diseases’’ are permissible
structure-function claims.52 Hence, general statements regarding body systems, such as ‘‘promotes
50Proposed Rule, Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product
on the Structure or Function of the Body, 82 Fed. Reg. 23624 (1998) (proposed April 29, 1998)
51FDA Final Rule, Regulations on Statements Made for Dietary Supplements Concerning the Effect of the
Product on the Structure and Function of the Body, 65 Fed. Reg. 999 (2000)
52See supra note 48, at 23,626
16relaxation’’ or ‘‘increases mental awareness,’’ are allowable.
Similarly, the FDA construes references to abnormal conditions, or to the typical signs or
symptoms of a specific disease, as implicit disease claims. Claims relating to general maintenance
of bodily functions are permitted, and the FDA rationalizes that some of these general signs
and symptoms ‘‘may be associated with a number of disease, but are not, by themselves, sufficient
to characterize specific diseases.’’53 Again, the problem here is that the test for differentiating
the types of claims is very slight. I do not think there is enough of a difference between,
for example, a presently impermissible claim of ‘‘lowers cholesterol’’ and a permissible claim
of ‘‘maintains cholesterol levels’’, to justify the existence of significantly lower thresholds
of regulation for the more general claims.
Because many claims that are permissible under the DSHEA are so difficult to distinguish from
drug claims, they raise the same concerns that new drug claims pose for the consumer and the
government despite the disclaimer that instructs the consumer not to depend on the product
as an FDA-approved drug. In this difficulty, we see the clash between the consumer’s and the
government’s interests in ensuring safe, effective health products and DSHEA’s promotion of
the consumer’s other interest in having access to dietary supplements and the information necessary
to exercise that freedom to make personal health choices.
This clash between interests lends itself to aspects of how DSHEA fails as a regulatory instrument.
For example, for the average consumer who wishes to use dietary supplements to treat or improve
negative health conditions, DSHEA fails in the sense that the average consumer is compelled
to take a risk when making his decision as to which dietary supplement to use. The labeling
on these products often contains claims suggesting the product’s therapeutic potential. However,
53Id.
17paradoxically, the legally required disclaimer that accompanies the product, stating that the
FDA has not specifically endorsed such claims, tells the average consumer to be aware and skeptical
of these claims relating to the product’s potential effects. This sending of mixed messages
only promotes confusion and ambiguity, elements that we should strive to avoid in connection
with consumer health and safety.
Moreover, under the current state of DSHEA and FDA regulation of such products, the average
consumer has a very difficult time in making an accurate judgment of the product’s efficacy
or even safety; products could potentially produce unintentional results and even cause unwanted
side effects for the unknowing consumer. It is not difficult to see how the new regulatory
scheme under DSHEA can raise important safety and efficacy issues for the average consumer
who wishes to use dietary supplements as alternative methods of treatment for certain health
conditions.
While it is certainly arguable that the FDA’s rules are a reasonable effort by the agency to
comply with DSHEA’s broadening deregulation, there are undoubtedly difficulties in the applications
of the rules, as mentioned above. Even for an expert in the field, it would be difficult to
differentiate some of the claims as permissible or impermissible under the FDA’s rules. Again,
one of the most important concerns here relates to the average consumer, who could be misled
by questionable claims on dietary supplements. We cannot blame the FDA for DSHEA’s vagueness,
but the line that the FDA has tried to draw is also vague and potentially problematic.
The method of how manufacturers label their supplement products with ‘‘non-disease’’ claims
has been described as ‘‘an art form of doublespeak,’’ with medical uses being implied, but
still almost obvious as in the example of claims to ‘‘promote prostate health.’’54 The FDA
54Editorial, Alternative Medicine -- The Risk of Untested and Unregulated Remedies, 339 New Eng. J. Med.
839, 841 (1998)
18seeks to draw the line between disease prevention and maintenance, but it is a line that can
too often be circumvented. Consumers can potentially misinterpret dietary supplement claims
related to maintenance as meaning that the product is necessary for maintenance, thereby steering
these consumers away from other, perhaps safer and proven methods of maintaining that particular
body function. This element of potential deception on the part of manufacturers is enough
to warrant reconsideration of the current test for claims. Furthermore, the federal courts
have not receptive to increased efforts by the FDA to inspect and pursue questionable claims.
For example, in Pearson v. Shalala, the D.C. Circuit held that the FDA may not prohibit the
marketing of dietary supplements with health claims when there is evidence to support those
claims.55 The permissibility of these claims stands even if the evidence is not conclusive.56
In light of class discussions in Professor Peter Hutt’s Food and Drug Law course, we must recognize
that the FDA is not an all-powerful super-agency, but an agency that is still constrained by
budget and other resource allocation factors. With the shifting of the burden of proof to
the agency to prove a specific dietary supplement’s harmfulness, it is much more expensive
in terms of resource constraints for the FDA to pursue every product.57 It is inevitable that
although DSHEA in its language still indicates the commitment of the government to the safety
and well being of the dietary supplement consumer, the regulating agency in this case is simply
not able to thoroughly enforce the stated goals of DSHEA.
While DSHEA permits supplements to make claims without prior approval by the FDA, the claims
are still required to have substantiation, by law. The difficulty of enforcement also arises
here in that the FDA lacks the express authority to obtain the records and studies of food
and supplement manufacturers. Lacking this authority, it is significantly more difficult for
55Pearson v. Shalala, 164 F. 3d 650 (D.C. Cir. 1999), reh’g en banc denied, 172 F.3d 72 (D.C. Cir. 1999)
56Id.
57See generally 1 James T. O’Reilly, Food and Drug Administration §10.15 (2d ed. 1995).
19the FDA to regularly inspect the studies the supplement manufacturers have supposedly undertaken
in order to substantiate their claims on their supplement products.
All of the above problems with regard to DSHEA and its enforcement points to the necessity
of scrutinizing whether DSHEA is an adequate method of protecting consumers from unsafe products.
With the explosion of dietary supplements on the market, it is not unreasonable to assume that
many consumers experiment with these products because they regard them as safe. Consumers
may falsely believe that these supplements are just as safe as traditional foods because they
are ‘‘dietary supplements,’’ a potentially vague and not fully defined term for the typical
consumer. The exemption of dietary supplements from FDA pre-market approval under the DSHEA
for safety amplifies this concern.
One of the main problems with dietary supplements is simply that we, including the scientific
community and the consumers, do not know enough about them due to lack of experience or study.
According to the FDA, the safety and benefits of ‘‘many’’ supplements on the market has not
yet been proven by adequate testing.58
Because of the incomplete information we have regarding many dietary supplements, this points
to one of DSHEA’s most important weaknesses: the lack of a requirement for dietary supplement
manufacturers to affirmatively substantiate the safety of their products. DSHEA does have
a requirement for safety substantiation, but the statute limits this requirement to new ingredients
that are sold after 1994.59 Furthermore, ‘‘new’’ ingredients are not to include any dietary
ingredient marketed prior to the passage of DSHEA, even if the ingredient was for a different
use.60
It almost seems obvious that all supplements should have to substantiate their safety at the
58Final Claims Rule, 65 Fed. Reg. 999, 1003 (2000)
5921 U.S.C. §350(b) (1994)
60Id.
20very minimum, but that does not even appear to be the case under DSHEA. A requirement for universal
safety substantiation would appear to be very helpful for the protection of consumers. Manufacturers
would be required to undertake scientific studies and tests on their products, and this would
contribute to better assessing the risks associated with the product use and establishing safe
amounts of the product to be consumed.
As some have argued, since the passage of DSHEA, ‘‘chaos’’ has taken over the dietary supplement
market.61 This ‘‘chaos’’ is not even necessarily limited to some unpredictability related
to the products in themselves. From my own experience having been raised in a very traditional
Chinese family, I am familiar with the use of certain herbal substances and other products
for medicinal purposes. I may not completely understand the technical science behind the substances
and their therapeutic effects, but I am a supporter and proponent of their efficacy, as I have
seen the results and cannot contest them on a scientific basis. From my experience and from
my understanding of my culture’s experience with these alternative medicines, the traditional
use of these products is safe and certainly effective, and it is logical to conclude that the
traditional use and preparation of these substances was the natural result of process of trial
and error over the long history of their use, and this has narrowed the use of these substances
to only the safe and more effective prescriptions/versions.
To make an analogy, a modern dietary supplement’s lifetime on the product market for a substantial
amount of time is partially reflective of its safety and effectiveness for similar reasons
why certain Chinese herbal prescriptions have lasted so long in their use and availability.
However, DSHEA alters this in the sense that it encourages a market where dietary supplement
manufacturers experiment with the products they market. If we examine just the herbal supplement
61Jane E. Brody, ‘‘Americans Gamble on Herbs as Medicine: With Few Regulations, No Guarantee of Quality,’’
N.Y. Times, Feb. 9, 1999, at D1.
21market, we see that manufacturers sometimes make their own herbal combinations to make new
products that haven’t survived the test of time that the more traditional herbal products have.62
Manufacturers also promote traditional products for new, less proven purposes.63 The products
may also differ from the traditional ones in the form they take when marketed, whether it be
as a pill, capsule, powder, tea, etc. And perhaps most egregiously, manufacturers can also
sell their products in a diluted or less effective form because it leads to cost cutting for
their production processes.64
V. Ephedra -- An Example of a Dietary Supplement Exploiting the Problems Associated with DSHEA
and its Enforcement by the FDA.
I will use ephedra as the example for this paper’s examination of how a dietary supplement manufacturer can
potentially abuse the provisions of DSHEA and its enforcement at the consumer’s expense. Ephedra, also
known as ma huang in Chinese, is an herb that has been used in the Chinese herb for centuries. Chemically,
it is referred to as ephedrine or as an ephedrine alkaloid, and its composition is close to the over-the-counter
drug pseudoephedrine, commonly found in cold medicines. Under traditional use in Chinese culture, ephedra
is used as a decongestant for symptoms resulting from colds, allergies, hay fever, and asthma. As evidence
of agreement in this use of product in this respect, the FDA has even approved ephedrine for use in cold
medicine as well.65
However, because of the holes that DSHEA leaves for manufacturers, which were discussed previously, we
62Varro E. Tyler, ‘‘Get the Best Herbal Medicine: Golden Rules to Guide You Safely Through the Herb
Aisles,’’ Prevention’s Guide: Healing Herbs, March 2, 1999, at 18
63See infra note 52 and Jim O’Brien, Herbal Cures for Common Ailments, at 96, (1998)
64Jane E. Brody, ‘‘’Natural, Drug-Free’ Herb May Have Risks of Its Own,’’ N.Y. Times, Feb. 9, 1999, at D6
65Paul D. Rheingold, ‘‘Herbal Supplements May Be Dangerous: Supplements May Look Like Magic Bullets for
Health Problems, But Users May Be Playing Russian Roulette,’’ Trial, Nov. 1999, at 42, 45
22have seen dietary supplements containing ephedra or ephedrine marketed in this country with vague claims
such as being an energy or metabolic enhancer or even a fat burner. This is the major hole that is the
result from DSHEA’s language allowing dietary supplement manufacturers to imply both non-traditional
and traditional therapeutic uses by using structure-function claims without having to obtain pre-market
approval from the FDA. This is very troubling considering most American consumers are not knowledgeable
of the traditional uses and eﬀects of the product and could be persuaded by such vague and even deceptive
advertising.
This is even more troubling when one considers some recent studies and commentaries on the abuse of
ephedra. The New England Journal of Medicine undertook a study on the health risks of ephedra, and
the authors of the article concluded that thirty-one percent of the one hundred forty adverse reports sent
to the FDA involving ephedra were deﬁnitely or probably related to its use.66 The more serious potential
side eﬀects of its use were described to either aﬀect the cardiovascular or central nervous system. Products
containing ephedra can speed up the heart rate and increase blood pressure, which could potentially lead
to stroke, seizures, hypertension, and cardiac arrhythmias. The article continues by describing the likely
reasons for the side eﬀects, including constriction of the arteries and shortening of the cardiac refractory
period brought on by the use of ephedra and other related alkaloids. However, under the provisions of
DSHEA, ephedra supplements are not required to contain directions for use and contraindications on their
labels, or any other additional warnings about the product’s potential side eﬀects. Thus far, the FDA has
reported approximately forty deaths and hundreds of serious injuries, primarily involving cardiovascular
problems, in connection with the use of ephedra.67
In addition to the inherent risks of ephedra, other studies have cautioned that it is often diﬃcult for the
consumer to know exactly how much active ephedrine is contained in the products that they purchase or
66Haller & Benowitz, ‘‘Adverse Cardiovascular and Central Nervous System Events Associated with the Dietary
Supplements Containing Ephedra Alkaloids,’’ New England Journal of Medicine, Dec. 2000.
67FDA Statement on Street Drugs Containing Botanical Ephedrine, HHS News, Apr.10, 1996
23which of the many diﬀerent alkaloids are being added. It is not uncommon to ﬁnd drastically diﬀerent
amounts of the substance than from what is indicated on the product label, and it is even possible to
ﬁnd instances where the amount of ephedra diﬀered by 2.4 times the labeled amount.68 Under DSHEA,
the manufacturers do not have to guarantee that the ephedra product contains the actual levels stated on
the labels, or that the ephedra was extracted from the part of the plant that traditionally is considered
necessary for eﬀective use.69 For ephedra and other herbal products, DSHEA requires manufacturers to
name each ingredient, its quantity, and the part of the plant where it was extracted. The problem here is
that DSHEA only requires the disclosure of the daily percentage value of the ingredients for which that daily
percentage value has been established, however, that value has not been established for ephedra and many
other substances that are sold in dietary supplements.
As mentioned previously, the FDA faces practical resource and time constraints in its eﬀorts, and the DSHEA
has dramatically aﬀected the agency’s approach to regulation of these dietary supplements. In our example
using ephedra, from one perspective, it is very disturbing that it took the FDA four years, and more than one
hundred reports of life-threatening symptoms and thirty-eight deaths, to take action against the product.
As this example will illustrate below, DSHEA has forced the FDA into a much more passive regulatory
role, employing methods that promote consumer knowledge and awareness of safety and eﬃcacy issues, as
opposed to an aggressive regulatory role where the agency could make a unilateral decision to just remove
the product from the market and subject it to further and more thorough testing.
Under the current safety provisions of the DSHEA, the diﬃculty and resource pressures of monitoring
dietary supplements is further evidenced by the FDA’s ongoing eﬀorts to control the level of ephedrine in
supplement products. The FDA’s proposed rule in regulating ephedrine identiﬁed eight hundred adverse
68‘‘Herbal Remedies: The Market is a Bit Too Free’’, Business Week 75 (Sept.4, 2000)
69Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, §7, 108 Stat. 4325, 4329-31
(1994)
24events associated with supplements containing the substance.70 The proposal sought to limit the individual
ephedrine dosage levels, the duration of use to not in excess of seven days, and it also called for a warning
stating that exceeding the limits of ephedrine “may cause heart attack, stroke, seizure, or death.”71 Under
the proposal, the FDA would have allowed claims relating to short-term eﬀects such as increased alertness
or energy levels.72 However, the proposal disallowed any claims relating to long-term eﬀects such as weight
loss.73 Still, this eﬀort by the FDA is not yet conclusive as the FDA later partially withdrew its proposal
to limit ephedrine use, in light of a GAO recommendation that the FDA obtain stronger evidence for its
proposal.74
In light of the inconclusive result of the FDA attempt at regulating ephedrine, I am concerned with the
weight loss claims on such supplement products. If such claims are permissible, at the minimum, the FDA
has to ensure that the labeling is entirely clear about the intended use of the product and the potential
consequences of its misuse. The regulators have to recognize the possibility that without very clear warnings
on the labels, there will be some consumers who choose to exceed the label’s limits. Moreover, in connection
with the safety of the product, one inevitably has to consider the substantiation of the claim being made.
If the eﬀectiveness of the weight loss claim cannot be substantiated, that is another reason to disallow such
claims. The substantiation of the claim should be viewed in conjunction with the safety of the product to
make a proper assessment whether to allow the claim or not.
Disclosing proper use and potential harms on the labeling on these dietary supplement products is especially
important when they pose potential health risks. The FDA sought for such information in their proposed
rule for ephedrine by having the label indicate the risks of heart attack, stroke, seizure or death, but perhaps
they could take the even further step of requiring a very clear and conspicuous disclosure of the warning as
70Proposed Ephedrine Rule, 62 Fed. Reg. 30,677, 30,678 (1997)
71Id.
72Id. at 30,718
73Id. at 30,697
74Dietary Supplements Containing Ephedrine Alkaloids; Withdrawal in Part, 65 Fed. Reg. 17,474 (2000)
25with cigarettes. Considering the very real risks associated with overuse of the product and considering the
potential for overuse if weight loss claims are allowed, this seems to be a prudent preventive measure.
Perhaps it would be wise to raise the standards of labeling for dietary supplements even higher. The labeling
may need to provide information to consumers regarding the increased risk factors.75 It does not seem an
unreasonable goal to try to make the information on product labeling regarding the product’s risks even
more tangible for the users. Sometimes, scientiﬁc and medical warnings by themselves are dismissed by the
average consumer as irrelevant information that does not really apply to him or her.
One suggestion to make label warnings more tangible is to actually provide concrete examples of what
can happen if the product is misused. Another possibility is to regulate dietary supplements in a manner
more resembling how drugs are regulated. This would include the options of limiting the distribution
and availability of certain potentially dangerous dietary supplements or also having a requirement for a
prescription in order to obtain the supplements. The opportunity to consult a physician before using some
of the more potent dietary supplements would certainly mitigate safety issues associated with the products’
overuse. These suggestions are still merely suggestions because it is not clear whether or not the FDA, under
current law, has legitimate authority to pursue such measures.
Ephedra use is increasing in the United States, just as the use of all dietary supplements is. Currently,
ephedra can be found in hundreds of products, and it is not limited to just products sold in tablet or capsule
form. The average consumer is able to ﬁnd ephedra in teas, sport and other health bars, and even in
beverages. In light of ephedra’s and other dietary supplements’ widespread status in the market, we should
be very concerned that DSHEA has made it diﬃcult for the consumer, who wants to use these products for
a traditional purpose, to accurately judge whether it is safe and to ﬁnd the right product, in terms of correct
dosage amount and source of substance extraction. Dietary supplements like ephedra, whose claimed eﬀects
75See note 66 at 30,692
26parallel the eﬀects of traditional regulated drugs, pose a unique public health threat due to their lowered
levels of regulation resulting from their designation as dietary supplements and not as drugs.76 Many dietary
supplements, especially herbal products, are often automatically perceived by consumers to be safe because
something about a natural product implies safety, which is obviously not always true.
Even in its victory with the passage of the DSHEA in 1994 and with its newly found ease in selling dietary
supplements, the giant supplement manufacturer industry is still not content, and it has pressed forward
for even more autonomy from government supervision and regulation on its products. For instance, the
manufacturers have approached Congress to lobby for the passage of the “National Food Uniformity Act of
2000,” which would signiﬁcantly limit the right of states to regulate the use of ephedra and other dietary
supplements. The passage of such legislation would directly aﬀect certain proposed laws in some states that
seek to add health warnings to dietary supplement products that contain ephedra.
VI. FTC Regulation and Other Potential Litigation Against Dietary Supplement Manufacturers
The FDA regulation of dietary supplements is just one important perspective to view these products from.
There are other standpoints from which dietary supplement regulation and litigation should be viewed from
in order to paint a more complete picture. Thus far, much of the discussion has focused on the problems
of DSHEA and the regulatory scheme of dietary supplements from the FDA’s perspective. However, these
problems have translated into other substantial problems for the multitudes of users of these products, re-
sulting in various litigation against the supplement manufacturers, which is a form of private, as opposed to
76Sean Harmon, Comment, ‘‘Melatonin Mania: Can the FDA Regulate Hormonal Dietary Supplements to Protect
Consumer Interests in Light of the Dietary Supplement Health and Education Act of 1994?’’, 22 U. Dayton L.
Rev. 77, 91-94 (1996)
27governmental, regulation of the industry. The usual areas of law that courts refer to in dietary supplement
litigation are federal trade laws and also products liability law. The following provides a brief overview of
government regulation from the Federal Trade Commission’s (FTC) perspective, because of its involvement
in the enforcement of federal trade laws, and of other litigation and legal actions that have arisen in connec-
tion with federal trade and products liability law in the dietary supplement industry.
In connection with federal trade law, the Federal Trade Commission and the FDA divide the responsibilities
of regulating dietary supplements. The FTC claims responsibility over advertising, which includes television
commercials and infomercials, health catalogs, and broadcast and print advertisements.77 As indicated ear-
lier, the FDA takes the responsibility for overseeing the product’s labeling, packaging materials, information
pamphlets, and other promotional materials that may be distributed at retailers.78
The FTC presence in the regulatory landscape was highlighted when on October 5, 2000, Weider Nutrition
International agreed to a $400,000 settlement with the FTC concerning charges that the company had made
unsubstantiated eﬃcacy and safety claims for its PhenCal products. The company placed advertisements
in major newspapers such as the New York Times and Washington Post claiming that their products were
“Proven Safe Without a Prescription,” “Proven Eﬀective as Prescription Treatments,” and “Proven to De-
crease Food Cravings.”79 The ads further declared that the products “cause signiﬁcant weight loss,” are as
“eﬀective as Phen-Fen,” “signiﬁcantly reduce food cravings and eating binges” and “prevent the regaining
of lost weight.”80
The FTC’s industry advertising guide provides a general overview of the various factors that manufacturers
and advertisers need to be aware of with regard to federal trade law. According to the FTC guide, the
77Federal Trade Commission, ‘‘Dietary Supplements: An Advertising Guide for Industry,’’
http://www.ftc.gov./bcp/conline/pubs/buspubs/dietsupp.htm
78Id.
79Vani Singhal, FDA’s Regulation of Dietary Supplements Fueled by Industry Growth, 1 Pharmaceutical & Med.
Devices L. Bull. 5 (2001)
80Id.
28truth-in-advertising law can be broken down into two commonsense propositions: 1) advertising must be
truthful and not be misleading to the consumers, and 2) before disseminating an ad, advertisers must have
adequate substantiation for all objective product claims.81 These principles are articulated in the FTC’s
Deception Policy Statement82 and Advertisement Substantiation Policy Statement.83 Moreover, the FTC
has the authority to challenge unfair trade practices. Unfair trade practices are deﬁned as actions that cause
or would be likely to cause substantial injury to consumers, which is not reasonably avoidable by consumers
themselves and not outweighed by countervailing beneﬁts to consumers or competition.84
The majority of litigation and investigations involving advertising are brought under the FTC’s deception
authority.85 An ad will be deemed deceptive if it is violation of the basic two propositions of the truth-in-
advertising law. The FTC will hold an advertiser equally liable for claims that are expressly deceptive as well
as claims that are impliedly deceptive.86 As a result, the FTC will examine an advertisement as a whole,
including text, illustrations, and the product name, and determine if it is deceptive. Relevant information
regarding safety and health risks are required to be disclosed to the consumer.
The FTC substantiation standard is a ﬂexible one that depends on many factors, including type of claim,
cost or feasibility of substantiation, the potential harms of a false claim, and also what level of substanti-
ation experts in the ﬁeld have determined to be reasonable.87 The manufacturers must have a reasonable
basis for substantiation, and claims regarding the eﬃcacy and safety of dietary supplements are held to a
substantiation standard of “competent and reliable scientiﬁc evidence.”88
The major problem occurs if we examine the last several decades, where the FTC has moved away from
industry-wide regulation to an individual case-by-case enforcement. Their enforcement standards have usu-
81See supra note 77
82Federal Trade Commission, ‘‘Deception Policy Statement,’’ http://www.ftc.gov/bcp/policystmt/ad-decept.htm
83Federal Trade Commission, ‘‘Advertisement Substantiation Policy Statement,’’ http://www.ftc.gov/bcp/guides/ad3subst.htm
84See supra note 77 at footnote 5
85Id.
86See supra note 77
87Id.
88Id.
29ally been more lenient and ﬂexible than their FDA counterparts.89 Their enforcement policy statement
indicates at one point that “there may be certain limited instances in which carefully qualiﬁed health claims
may be permitted under section 5 [of the FTC Act] although not yet authorized by the FDA.”90
Thus, the dietary supplement industry has generally favored the FTC enforcement policies over those of the
FDA’s. In 1954, the FTC and FDA originally agreed to divide their responsibilities between food advertising
and product labeling, respectively.91 It is interesting to note that although at the time of that agreement it
may have been sensible for the FDA to rely on the FTC to regulate food advertising, it certainly no longer
seems as appropriate to rely on the FTC, an agency with considerably less scientiﬁc training and background,
when we observe the current trend of food advertisements that are replete with claims involving more com-
plex scientiﬁc and health issues. The FTC, in its Enforcement Policy Statement on Food Advertising, states
that it would defer to the FDA’s scientiﬁc expertise.92
However, it is not clear that the FTC takes the necessary enforcement actions against violating claims in
advertisements, even though the FDA has not approved those claims for labeling.93 There are several note-
worthy examples here. First, several years ago, Welch’s Foods, Inc. advertised that “[g]rowing evidence
suggests that diets rich in antioxidants may reduce the risk of some cancers...” and then pointed out that
“...Welch’s purple grape juice has more than three times the naturally-occurring antioxidants of other pop-
ular juices.”94 Even though the FDA had rejected the health claim that antioxidants may reduce the risk
of some cancers due to lack of signiﬁcant scientiﬁc agreement, the FTC still did not engage in any action
against those claims in the advertisements. Another example occurred with Heinz and its ketchup products.
Heinz had advertisements that made that claim that lycopene, a substance in its product, “may help reduce
89Federal Trade Commission ‘‘Enforcement Policy Statement on Food Advertising,’’ http://www.ftc.gov/opa/predawn/F95/adlabelharmony.htm
90Id.
91Working Agreement Between FTC and FDA, 3 Trade Reg. Rep. (CCH) ¶ 9,851 (1971)
92See supra note 89
93Ilene Ringel Heller, ‘‘Functional Foods: Regulatory and Marketing Developments,’’ 56Food & Drug L.J. 197
(2001)
94Id. at 216.
30the risk of prostate and cervical cancer.”95 Such a claim would clearly be illegal on the product labeling,
however, Heinz was able to make such a health claim on the advertisements. The FTC informed Heinz
that it may have violated some substantiation standards, and Heinz stopped that particular ad campaign.
The FTC, however, has not followed through with Heinz’s similar claims in its promotional materials to the
media.96 So, the key point here is that while the FTC is supposed to defer to the FDA in the arena of
scientiﬁc and medical issues, it does not always do so. It is also interesting to point out that these omissions
in complete regulation shows that the FTC faces the same enforcement problems as the FDA in terms of
lack of resources and prioritizing other regulatory duties.
Moving on from federal trade law as a potential basis for claims against dietary supplement manufactur-
ers, the other signiﬁcant area of law to examine in connection with these claims is products liability law.
Litigation involving dietary supplements is still an area that is developing; therefore it would be helpful to
examine examples involving pharmaceutical products, including prescription and over-the-counter drugs, to
gauge what potential claims may be brought against dietary supplement manufacturers.
Generally speaking, a plaintiﬀ may bring various claims against a commercial seller or distributor of a phar-
maceutical product. Perhaps the most often seen claims against pharmaceutical companies are characterized
by defects that are related to insuﬃcient product warnings or instructions, otherwise known as the com-
pany’s duty to warn.97 In traditional products liability law involving pharmaceutical prescription drug, the
learned intermediary rule is recognized to stand for the proposition that “a drug manufacturer fulﬁlls its
legal obligation to warn by providing adequate warnings to the health-care provider”.98 The Restatement,
Third, rationalizes this rule by stating, “only health-care professionals are in a position to understand the
signiﬁcance of the risks involved and to assess the relative advantages and disadvantages of a given form of
95Id.
96Id.
97Restatement of the Law, Third, Torts: Products Liability §6, comment d. (1998)
98Id. at comment e
31prescription based-therapy.”99
Regardless, it appears that dietary supplement manufacturers would not have this same defense at their
disposal, or at least have a much more diﬃcult time asserting it, for several telling reasons. First, dietary
supplements diﬀer from traditional prescription drugs in the sense that the consumer is able usually able
to obtain the product without a doctor’s prescription. In this way, dietary supplements are more akin to
over-the-counter drugs. There have been cases where nutritionists recommended certain products for their
clients, thus playing an analogous role to doctors making prescriptions for their patients.100 In these cases, it
is certainly feasible to imagine a scenario where the nutritionist or trainer would be held liable like doctors,
and hence shielding the manufacturer from liability.
Again, however, there is another reason why it is harder to for supplement manufacturers to assert this
defense; it is not clear that the relationship between a nutritionist or trainer and the client creates the same
kind of inviolable relationship that exists between the physician and patient. Then, even if there is an actual
physician involved, it is not clear that the supplement manufacturer would be able to reliably depend on the
defense as DSHEA has made it diﬃcult occasionally for even physicians to obtain full information regarding
certain products.
Still, supplement manufacturers would be prudent to not depend on the learned intermediary rule as a safety
net because most of the time, there really is no physician involved in the use of dietary supplements. So, the
manufacturers still need to be most wary of providing suﬃcient warnings directly to the consumers, much
like with over-the-counter drug products. The warnings should be directed to any information or risks the
consumer needs to be aware of regarding any substances in the product that may have potential adverse
health eﬀects. While it is true that the manufacturers will have to be in compliance with FDA regulations
regarding labeling, compliance does not equate to being fully shielded from potential consumer claims against
99Id. at comment b
100See supra note 65, at 46
32the product. The gap between products liability common law’s duty to warn and the standards set by federal
regulation suggests that there is potential for manufacturer liability even if there is regulatory compliance.
The other platform within products liability law where dietary supplement manufacturers can be exposed to
potential claims is the doctrine of defects. Again, it would be helpful for supplement manufacturers to look
at the law regarding prescription drugs. According to the Restatement, Third, a drug may be considered
defective if it contains a manufacturing defect, or is not reasonably safe due to defective design, or it is not
reasonably safe due to inadequate instructions or warnings.101
Pharmaceutical manufacturers may be exposed to strict liability for harms suﬀered by plaintiﬀs that result
from a manufacturing defect.102 The Restatement deﬁnes the condition when a drug contains a manufactur-
ing defect as when “the product departs from its intended design even though all possible care was exercised
in the preparation and marketing of the product.”103 If strict liability is found to apply, then a manufacturer
will be liable even if the plaintiﬀ is unable to prove that the manufacturer should have discovered the defect
or even was aware of it.104 Strict liability is a very powerful doctrine, and dietary supplement manufacturers
deﬁnitely are cautious of it. As consumers, we would like to think that the threat of being exposed to strict
liability would pressure manufacturers to have higher standards of research and production. Also, similar to
the issue of duty of care, compliance with FDA dietary supplement regulations does not necessarily shield
the manufacturer from a manufacturing defect claim.
VII. Possible Changes to Improve the Current Regulatory Scheme
101Restatement of the Law, Third, Torts: Products Liability §6(b) (1998)
102Id. at §2, comment n
103Id. at §2(a)
104Werner v. Upjohn Co., 628 F.2d 848 (4th Cir. 1980), cert. denied, 449 U.S. 1080 (1981) (stating that a
plaintiff only has to show that the defendant placed the drug on the market)
33After considering the above, there is clearly plenty of opportunity for costly, time-consuming litigation and
government enforcement actions in the area of dietary supplements. In light of that, it would also be rel-
evant to examine what potential changes can be made to the regulatory scheme to attempt to maximize
consumer awareness and safety, minimize manufacturers’ abuse of the regulations, and minimize litigation
and government actions that are provoked by the occurrence of severe adverse health eﬀects and hazards.
The obvious answer for an ideal situation, strictly in terms of consumer safety, is to start treating the cat-
egory of dietary supplements the same way as drugs in the arena of government regulation. However, the
passage of DSHEA prevents the FDA from approaching the issue in this way. In addition, even though there
have been more serious consequences of DSHEA relating to safety and manufacturer abuse of the regulations,
there is still another important consideration, and that is the purpose behind DSHEA in the ﬁrst place. One
of the major driving forces behind DSHEA was to increase consumer freedom and choice. Although DSHEA
has not been the ideal vehicle for attaining these goals, these goals are still legitimate concerns that should
be incorporated by our regulatory scheme. Regulating supplements in the same vein as drugs deﬁnitely
sacriﬁces these later goals in favor of ultimate consumer safety.
Once again, in connection with these concerns, I would like to bring up my own Chinese heritage and positive
experience with products that would be labeled under dietary supplements in the American market. Many
of these products have very real health beneﬁts that Western science seems to want to disbelieve or avoid
further testing and research to conﬁrm the eﬀects. These herbs and other substances have been used in the
Chinese culture safely for longer than probably any prescription medicine in the American market today.
Not only are they safe when properly used and in accordance with tradition use guidelines, but also, in my
mind, it is unquestionable that there are health beneﬁts associated with their use. It is baﬄing when I read
commentators who question the existence of any beneﬁts with their use. It would be almost an injustice to
deny consumers access to safe and eﬀective dietary supplements such as the ones I have had experience with.
34With the case for consumer freedom and choice stated, however, the safety and eﬃcacy of dietary supple-
ments are just as important, if not more so. Therefore, the possible solutions that follow are ones that
represent a compromise between the conﬂicting interests of safety versus complete freedom and access to
the products. The ideals of consumer freedom and the driving forces behind DSHEA are commendable.
The deception that is often involved in the marketing and promotion of these supplements as a result of
DSHEA’s new provisions are not. So, the min-max statement from the beginning of this section of the
paper should be amended to also seek to maximize consumer freedom choice, while maximizing consumer
safety and minimizing manufacturer abuses and resulting litigation. Assuming that the option for regulating
dietary supplements as traditional drugs is not available, we can examine some suggestions that might be
more feasible and agreeable to all parties as the regulatory scheme stands today under DSHEA.
It would seem that there is much room for improvement in the aspect of dietary supplement labeling. The
ﬁrst possibility is to have FDA require the placement of warnings on the labels explicitly indicating that
the FDA has not evaluated the safety and eﬃcacy of that particular supplement. With the FDA having
such high levels of credibility and faith with the general public, an FDA disclaimer on products would have
the eﬀect of making consumers consider their choice and use of products more carefully and ideally, also
with more knowledgeably. This solution would also be a compromise in order to try to increase one of
the DSHEA’s goals of consumer freedom and access.105 This is also consistent with the court’s ruling in
Pearson v. Shalala.106 In that case, even though the court ruled against the FDA in the particular fact
pattern, the language of the ruling still suggests that the FDA would not violate the commercial speech
doctrine and would still be allowed to use these disclaimers on products in order to address “misleading”
health claims.107
I also believe a major beneﬁt could be realized by requiring more substantive information on the labeling
105See supra note 35, at §4
106See supra note 55
107Id. at 657.
35in regards to a dietary supplement’s possible adverse health eﬀects if misused. Reading examples of actual
eﬀects that may occur to your body if misused certainly reinforces the eﬀect of a warning on consumers,
who arguably do not read labels and warnings closely enough. It is not even clear to me how eﬀective the
conspicuous and unambiguous warnings on cigarette packs, for example, are today on the cigarette consumer.
Perhaps warnings need to elevated to another level to catch the attention of people. A potential side eﬀect
of increased, heftier warnings is that manufacturers would then be given additional incentives to cooperate
with the FDA in terms of providing the agency with scientiﬁc evidence that substantiates the product’s
safety and eﬃcacy so their product can avoid the need to put such an alarming warning on the labeling.
Moreover, as mentioned previously, the issue of discrepancies between actual ingredient content and the la-
beling on the dietary supplement product could be addressed if the FDA established standards such as Daily
Recommended Allowance for the ingredients. Again, I realize that this suggestion involves a tremendous or
maybe even an impossible amount of resources in order to test and research the involved ingredients. How-
ever, in theory, it is a legitimate method to achieve the goals of reducing consumer deception and increasing
consumer safety and awareness.
Perhaps the most eﬀective change would be to address the tremendous loophole of allowing supplement man-
ufacturers to make structure-function claims. The diﬃculty in distinguishing the ﬁne diﬀerences between
some structure-function claims and claims that would require pre-market approval have been shown to be
slight. The FDA could make it more diﬃcult for manufacturers to take advantage of structure-function
claims by requiring these claims to be based on “universally recognized factual statements concerning known
and substantively signiﬁcant relationships regarding the eﬀect of a substance on the structure or functioning
of the body.”108 For example, established, concrete claims such as “calcium is necessary for bone growth
and development” or “Vitamin A is necessary for good vision” would be permissible.109 However, unsub-
108See note 93 at 219
109Id.
36stantiated, vague claims such as “antioxidants may play an important role in slowing changes that occur
with normal aging” or that “lycopene may help ensure normal functioning of the prostate gland” need to be
disallowed by the FDA until such claims can be substantiated.110
There are also other possibilities to improve the regulatory scheme aside from changing the practices regard-
ing supplement labeling. The FDA can also enforce another eﬀective rule in connection with new dietary
supplements that are introduced to the market. The agency could enforce the requirement for manufactur-
ers to produce documentation and other evidence that the substantiation requirement for safety has been
fulﬁlled.111 It is important to note that the FDA probably could not use this rulemaking power with respect
to existing, old dietary supplements. The aim of providing increased access to information regarding the
supplement products is clearly consistent with the min-max proposal from above and also with DSHEA’s
stated goals.
The FDA, in connection with over-the-counter drugs, has already raised the following proposal, and it sounds
like it is a promising step towards ensuring a higher level of safety and eﬃcacy of the products on the market.
In 2000, the FDA, in an eﬀort to make the over-the-counter drug approval process more ﬂexible, made the
proposal to consider foreign marketing experience when they had to evaluate whether a product can be
included in the over-the-counter monograph system.112 According to one author, the monograph system
is critical for OTC drugs because an “OTC drug product that does not meet monograph requirements is
considered to be an unapproved new drug for which a new drug application (“NDA”) must be ﬁled and
approved” before entering the consumer market.113 As mentioned, the NDA is a very costly process for
manufacturers, and the result for dietary supplement products, such as herbal remedies that are often sold
110Id.
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112Eligibility Criteria for Considering Additional Conditions in the Over-the-Counter Drug Monograph System:
Request for Information and Comments, 61 Fed. Reg. 51,625 (1996)
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37as drugs in most other countries, frequently is that they become sold in the safe harbor category of dietary
supplement in the United States.114 So, the logical step from these observations would be to also include
dietary supplements in the OTC monograph system, in order to subject them to the same higher standards
of eﬃcacy and safety as the OTC drugs. This seems to be a very good compromise between one extreme of
regulating dietary supplements in the same vein as traditional prescription drugs and the other extreme of
minimal regulation, as under DSHEA.
VIII. Conclusion
The growth in the use of dietary supplements is unquestionable. There are also numerous dietary supplements
on the market that have legitimate health beneﬁts. Consumer access to these supplements is also a worthy
goal, which spurred the passage of DSHEA. We have examined how the regulatory landscape behind dietary
supplements has evolved. The problem with the current state of dietary supplements appears to lie squarely
in the regulatory scheme that currently governs them. DSHEA has problems inherent in it, and there are
also problems with the regulation of dietary supplements by the FDA and FTC. This paper has discussed
some possible methods of improvement. Hopefully, these agencies can follow in that spirit and adjust to ﬁnd
new ways to preserve the ultimate goals of safety, knowledge, choice, and health.
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